Prescient Therapeutics (ASX:PTX) secured investigational new drug clearance from the US Food and Drug Administration to conduct a phase two trial of PTX-100 in patients with relapsed and refractory cutaneous T-cell lymphomas, according to a Monday filing with the Australian bourse.
The two-part trial will investigate the optimal dose of PTX-100 and its efficacy, the filing said. It will be conducted across 15 global trial sites.
The company's shares fell 4% in recent Friday trade.
Price (AUD): $0.05, Change: $-0.002, Percent Change: -4.08%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。